AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

Rhea-AI Summary

AbbVie (NYSE:ABBV) has initiated construction on a $70 million expansion at its AbbVie Bioresearch Center in Worcester, Massachusetts. The expansion is part of AbbVie's broader $10 billion U.S. investment commitment to enhance biologics manufacturing capabilities and capacity.

The project includes new biologics manufacturing areas and a three-story building for laboratory, warehouse, and office space. This investment will facilitate the transfer of select oncology products from Europe to the U.S. and support the production of current and next-generation oncology and immunology medicines. The expansion will create new jobs, adding to AbbVie's existing 28,000 U.S. employees, including over 2,000 in Massachusetts.

Positive

• Part of a larger $10 billion U.S. investment commitment for innovation and manufacturing expansion
• Creation of new jobs at the Worcester facility
• Expansion of domestic biologics manufacturing capacity to meet increased global demand
• Transfer of oncology product manufacturing from Europe to U.S.
• Enhancement of production capabilities for current and next-generation medicines

Negative

• Significant capital expenditure of $70 million requiring allocation of financial resources

Insights

Pharmaceutical Industry Analyst

AbbVie's $70M biologics expansion strengthens US manufacturing capacity for oncology/immunology medicines, supporting long-term growth strategy.

AbbVie's $70 million expansion of its Worcester Bioresearch Center represents a strategic manufacturing investment that strengthens the company's biologics capabilities in high-value therapeutic areas. This project is part of a broader $10 billion US capital investment commitment, highlighting AbbVie's confidence in its biologics pipeline and commitment to domestic production.

The expansion will specifically enhance manufacturing capacity for immunology and oncology biologics - the two therapeutic pillars that drive AbbVie's current growth following Humira's loss of exclusivity. By transferring select oncology production from Europe to the US, AbbVie is optimizing its global manufacturing network while potentially reducing supply chain risks and transportation costs.

The investment demonstrates AbbVie's long-term strategy of maintaining leadership in immunology while building its oncology portfolio. The Worcester site has historically been crucial for biologics development, and this expansion strengthens its role as a center of excellence. By increasing US-based biologics capacity, AbbVie positions itself to better meet growing global demand for complex biologic medicines, particularly as biosimilar competition intensifies for older products.

With 28,000 US employees including 2,000+ in Massachusetts, this expansion reinforces AbbVie's significant economic presence. The added laboratory, warehouse, and manufacturing capabilities will support the company's pipeline progression and commercial production needs for years to come, providing manufacturing flexibility as AbbVie navigates the post-Humira landscape.

• Expansion increases biologics manufacturing for immunology and oncology medicines
• Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing
• Furthers longstanding commitment to AbbVie's Massachusetts sites and workforce

NORTH CHICAGO, Ill., Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass., which serves as a center of excellence for biologics research and development and manufacturing. This expansion is part of the company's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical biologics manufacturing capabilities and capacity.

This investment will further expand AbbVie's domestic biologics manufacturing capacity to meet increased global demand and support U.S. production of current and next-generation oncology and immunology medicines. It will include construction of additional biologics manufacturing areas and a three-story building housing laboratory, warehouse and office space. Construction will enable the expedited transfer of select oncology products from Europe to the U.S.

"For more than three decades, ABC has been at the forefront of scientific innovation and biologics manufacturing," said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer, AbbVie. "This investment will further expand AbbVie's biologics manufacturing capacity and position ABC to build upon its impressive track record of developing, manufacturing and launching next-generation complex biologic medicines that improve the lives of millions of patients worldwide."

With a presence in all 50 states and Puerto Rico, AbbVie employs 28,000 people in the U.S., including more than 2,000 in Massachusetts. This expansion will create new jobs at the ABC site and add additional capabilities to AbbVie's U.S. manufacturing footprint, which supports more than 6,000 American jobs across 11 manufacturing sites.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.

Media: Gabby Tarbert    (224) 244-0111 gabrielle.tarbert@abbvie.com

Investors: Liz Shea (847) 935-2211 liz.shea@abbvie.com

 

View original content:https://www.prnewswire.com/news-releases/abbvie-begins-construction-on-70-million-expansion-to-further-increase-biologics-manufacturing-and-rd-presence-in-the-us-302571294.html

SOURCE AbbVie

FAQ

How much is AbbVie (ABBV) investing in its Worcester facility expansion?

AbbVie is investing $70 million in the expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts.

What is the purpose of AbbVie's Worcester facility expansion?

The expansion will increase biologics manufacturing capacity for immunology and oncology medicines, and includes new manufacturing areas, laboratory, warehouse, and office space.

How many jobs does AbbVie currently have in the United States?

AbbVie currently employs 28,000 people across all 50 states and Puerto Rico, including over 2,000 in Massachusetts.

What is AbbVie's total planned investment commitment in the U.S.?

AbbVie has committed to investing more than $10 billion of capital in the U.S. to support innovation and expand biologics manufacturing capabilities.

How will the Worcester expansion affect AbbVie's manufacturing operations?

The expansion will enable AbbVie to transfer select oncology products from Europe to the U.S. and enhance its domestic biologics manufacturing capacity for current and next-generation medicines.